Li, H., Ren, K., Jiang, T., & Zhao, G
Healthcare strategies to combat PASC, the novel virus-induced human metabolic syndrome, requires an in-depth understanding of the following: (i) the genomic and metabolomic (proteomic/lipidomic) signatures of SARS-CoV-2 and their interactions with host cellular metabolic machinery, (ii) the virus-induced HMRD and resulting pathophysiological manifestations in the onset and progression of COVID-19, (iii) the cumulative role of HMRD, symptomatic outcomes (disease spectrum), and comorbidities in systemic/multi-organ dysfunction during COVID-19, (iv) both virus- and host-mediated factors that contribute to transition of acute SARS-CoV-2 infection (COVID-19) into a persistent chronic state of virus-free PASC, (v) protracted effects of HMRD in tandem with patients history, in the development of new onset metabolic syndromes (i.e., T2DM, CVD, ME/CFS and POTS) among PASC patients, (vi) stratification/categorization of PASC patients based on persistent symptoms, organ/system involvement, and metabolic dysfunction for specific target-delivered health recovery regimens, and (vii) the structure-function activity of specific bio-functional dietary compounds in formulating precision nutrition protocols to reset SARS-CoV-2-induced HMRD in chronic PASC
Traveling with tirzepatide alongside semaglutide Some protocols involve transitioning between semaglutide and tirzepatide, or users may travel with both if they are in the process of switching from tirzepatide to semaglutide
A., Sadatmadani, F., Alikhani, R., Pishkari, Y., & Deravi, N
Inhibition of triosephosphate isomerase by phosphoenolpyruvate in the feedback-regulation of glycolysis
V.ProsperiJ
